Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHOENIx
PACTR202101800561159Phase 3Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases and National Institute of Child Health and Human Development
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of delamanid and isoniazid in multidrug-resistant tuberculosis (MDR-TB) and Tuberculosis (TB), sponsored by National Institute of Allergy and Infectious Diseases and National Institute of Child Health and Human Development. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
delamanidisoniazid
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)Tuberculosis (TB)
Beyond the preview
Go deeper on PACTR202101800561159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202101800561159.